Hauptinhalt

Klinische Studien

Abbvie M22-132
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

ABC-HCC
A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma 

Abiomed STEMI DTU
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI DTU Trial

ACO/ARO/AIO-18.1
A short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients. A randomized phase III trial of the German Rectal Cancer Study Group.

AIO-Studien-gGmbH TITAN TCC
A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma

ARASAFE
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with mHSPC

AstraZeneca POTOMAC
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC)

AstraZeneca WAYPOINT
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (WAYPOINT)

Biontech BNT122-01
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection

Boston Scientific, Register Kryoablation
Register zur perkutanen Kryoablation bei malignen Lungentumoren

Bristol-Myers Squibb (BMS) CA057-001
A Phase 3, two-stage, randomized, multicenter, open-label study comparing CC-92480, Bortezomib and Dexamethasone (480Vd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)

Bristol-Myers Squibb (BMS) CA209-274
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

Bristol-Myers Squibb (BMS) CA209577
A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)

Bristol-Myers Squibb (BMS) CA2098HW
A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer (CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW)

Bristol-Myers Squibb (BMS) CA224-104
A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb (BMS) CA224-127
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma

CABONEN
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3

FaPaCa
Nationale Fallsammlung familiäres Pankreaskarzinom

Gemoab (AvenCell) GEM3PSCA-01
A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSCA Marker

Genentech GB43311
Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Studie der Phase IIb zur Beurteilung der Wirksamkeit und Sicherheit von Astegolimab bei Patienten mit chronisch obstruktiver Lungenerkrankung

GlaxoSmithKline (GSK) ANCHOR-1, 217095
A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)

GMMG-CONCEPT
A Clinical Phase II, multicenter, Open‐label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I‐KRd) in Primary diagnosed high‐risk multiple myeloma  paTients

GMMG HD8/DSMM XIX
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma

Huya Bioscience HBI-8000-303
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Integrate IIb
A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

IRITACE
Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC).

ITM Solucin COMPETE
A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Janssen MajesTEC-9
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

mcBEST
Prospective multicenter study on effectiveness, technical feasibility and safety of reversible electroporation in sclerotherapy of patients with vascular malformations

Merck Sharp & Dohme (MSD) MK-1308A-008
A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Coformulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Merck Sharp & Dohme (MSD) MK-3475-630
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).

Merck Sharp & Dohme (MSD) MK4280A-007
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

Merck Sharp & Dohme (MSD) MK7684A-004
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies

MorphoSys MOR208C310
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus RCHOP in previously untreated, high-intermediate and high-risk patients with newlydiagnosed diffuse large B-cell lymphoma (DLBCL)

NEONAX, AIO-PAK-0313
Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313)

NIFE AIO-YMO/HEP-0315
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial

Novartis COMB157G2399, Alithios
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis

Pharmacept HEPASTAR
HEPAtocellular carcinoma: Management with transarterial chemoembolization with degradable STARch microspheres (DSM-TACE) – the HEPASTAR study

POLESTAR
Phase IIA trial of short-term chemotherapy and pembrolizumab, followed 
by Pembrolizumab and OLaparib as firstline therapy in Her-2 negative gastric/gastroESophageal-juncTion (GEJ) AdenocaRcinoma

PREDICT PACA
Co-clinical establishment of a prospective clinical database and biobank of fine needle biopsy material from metastases of patients with stage IV PDAC under real-life conditions for the clinical validation of the two-tiered PREDICT-PACA approach to precision medicine.

RamuNet
A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive welldifferentiated metastatic pancreatic neuroendocrine tumors.

Replimune IGNYTE, RPL-001-16
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors [IGNYTE]

Roche BO42592
A phase II, randomized, double-blind, placebo-controlled study of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin versus pembrolizumab plus pemetrexed and carboplatin/cisplatin in patients with previously untreated advanced non-squamous non-small cell lung cancer

Roche GO41892
A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-pd-l1/pd-1 antibody and platinum-containing chemotherapy

Roche YO42137, Skyscraper-07
A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab (anti-tigit antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma

SOLARIS
A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy